Tag: Health Care

Displaying 161 - 180 of 802 results.

I. INTRODUCTION It is an honor to be here and join such an impressive group of practitioners, government officials, judges, academics and economists to discuss the cutting edge issues confronting health care and antitrust.
As the title indicates, the settlement of pharmaceutical patent disputes is a subject that I have already addressed.(1) You may wonder why I am visiting it again. When I first discussed the issue last November, The Federal Trade Commission ("the Commission") had brought only two cases,(2) with a...
Good afternoon. It is a pleasure to be here today to discuss the antitrust analysis of physician networks and other integrated delivery systems. As always, I must remind you that my remarks today reflect only my own views and are not necessarily those of the Commission or of any other Commissioner.
Good morning. It is a pleasure to be here today to introduce this morning's program on the antitrust analysis of hospital mergers, HMO mergers and physician networks. I would like to express my sincere thanks to General Burson for his kind introductory remarks and for hosting this conference. As...
Good afternoon. Thank you for the opportunity to address the 30th Annual Antitrust Institute on Healthcare Antitrust Developments on what is a very interesting and exciting topic. Let me say before I begin that the views I express are entirely my own and do not necessarily represent the views of...
Mr. Chairman, the Federal Trade Commission thanks you and the members of the Committee for inviting us again this year to present the Commission's views on a proposed antitrust exemption to allow physicians and other health care professionals to engage in collective bargaining with health plans.
INTRODUCTION I appreciate the opportunity to speak to you today about an idea that we frequently hear raised in discussions about health care markets: the concept of "leveling the playing field." The idea of a level playing field -- and what role antitrust should play in bringing it about -- is...
Mr. Chairman and members of the Committee, I am pleased to appear before you today to present the testimony of the Federal Trade Commission concerning H.R. 2925, and the application of the antitrust laws to health care provider networks.1 This testimony will discuss what the Commission believes to...
As usual, my remarks today reflect my own views, and are not necessarily those of the Commission or of any Commissioner.
The views presented are those of author and do not necessarily represent those of the Bureau of Competition, or any individual Commissioner.
The views expressed in these remarks are my own, and do not necessarily reflect those of the Federal Trade Commission or any other individual Commissioner. These comments are an abbreviated version of a longer speech given at the Annual Conference of the National Association of Retail Druggists on...
Good afternoon, I'm very pleased to be here. I'd like to thank Howard and the ABA for inviting me. It's an added bonus that the ABA chose to hold this conference in beautiful San Francisco. I love this city. The FTC has a regional office here, so I have a great excuse to visit often.
It is a pleasure to be here to discuss antitrust issues of concern to hospitals. I would like to focus my remarks on two issues: (1) the recent revision of the Federal Trade Commission/Department of Justice Statements of Enforcement Policy in Health Care, particularly as the revisions apply to...
Commissioner, Federal Trade Commission. The views expressed are those of the Commissioner and do not necessarily reflect the views of the Federal Trade Commission or any other Commissioner or staff.
Good afternoon. It is a pleasure to be here today as a panelist for the Health Trustee Institute to discuss antitrust, hospital mergers, and innovation in health care delivery. As usual, the views I express are my own. They are not necessarily those of the Commission or any other Commissioner.
1. Introduction I want to thank the Healthcare Antitrust Forum for the invitation to talk about some recent developments in healthcare antitrust at the FTC.(1) An agency representative's usual response to such an invitation is a survey of cases across a spectrum, but I will not do that today....
The views expressed in these remarks are my own, and do not necessarily reflect those of the Federal Trade Commission or any other individual Commissioner. Thomas N. Dahdouh provided assistance in preparing this speech.

Pages